Drug screening

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Even with rigorous optimisation and validation, we face a 90% failure rate by the clinical phase1. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist […]

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations […]

Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services.   A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures, and Saker Capital.   […]

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences […]

ELRIG CEO Sanj Kumar tells readers how they can access the most exciting research and find the latest technologies to propel their projects forward at this year’s Drug Discovery 2022  At ELRIG, our purpose is to support researchers in the life sciences and drug discovery communities to learn, share, innovate, connect, and collaborate. We understand […]

Life sciences company Carterra has joined data cloud company TetraScience’s network of partners to help generate insights into the potential of antibodies as drug candidates.  The Tetra Partner Network (TPN) is an ecosystem of partners which connects R&D data for pharmaceutical and biopharmaceutical customers.   Carterra will connect its LSA high-throughput surface plasmon resonance (SPR) platform […]

This paid-for advertorial by Eurofins Discovery appeared in Volume 23 – Issue 3, Summer 2022. In the following article, Luke Oostdyk, Lakshmi Anantharaman and Nicole Servant from Eurofins Discovery discuss how G-Protein Coupled Receptor screening and profiling can advance drug discovery programs.  The sheer number of understudied and orphan receptors in the G-Protein Coupled Receptor (GPCR)1 […]

Biopharmaceutical company Orbit Discovery has been awarded almost £500,000 in a grant to help it expand its microfluidics screening capabilities.   The £472,000 Smart grant was awarded by Innovate UK and will facilitate the implementation of droplet-based microfluidics for cell-based functional screening and expand the capabilities and throughput of Orbit’s peptide display platform.  Orbit is currently […]

NanoTemper Technologies has launched a number of updates to its portfolio of instruments to help researchers working in drug discovery and adeno-associated virus (AAV) therapies.  NanoTemper Technologies has launched its Spectral Shift technology to remove the roadblocks experienced by scientists dealing with really complex molecular interactions often seen in challenging drugs and drug targets like […]

CAR T cell technology provides the foundation for established immunotherapies against certain types of blood cancer and holds great promise for the fight against many solid tumours too. One major drawback of conventional CAR T cell technology, which relies on a single target antigen, is the lack of tumour-associated antigens (TAAs) that are truly specific for cancer cells. […]